Wells Fargo Reiterates Buy Rating on RYTM
Wells Fargo maintained its buy rating for RYTM, setting a target price of $155, a 75.38% upside from the current price.
Key Points
- Wells Fargo reaffirmed its buy rating on RYTM, setting a price target of $155 as of June 15, 2026.
- Wells Fargo's $155 price target implies 75.38% upside from Rhythm Pharmaceuticals, Inc.'s ($RYTM) current $88.38 share price.
- RYTM shares were trading at $88.38, with analysts maintaining a positive outlook.
- Peers like RA Capital and BlackRock showed varied changes in their RYTM holdings recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wells Fargo has reiterated its buy rating on RYTM, setting a price target of $155. This announcement came on June 15, 2026, with the stock trading at $88.38 at the time.
Other Institutional Activity in RYTM
RA Capital Management, L.P. maintained its position in RYTM with 6,666,837 shares valued at about $579.8 million. BlackRock, Inc. slightly reduced its holdings by 60,183 shares, bringing its total to 6,237,151 shares worth around $542.4 million. Baker Bros. Advisors LP held steady with 5,604,483 shares valued at $487.4 million. Primecap Management Co/CA/ trimmed its stake by 61,160 shares, ending with 3,417,509 shares valued at approximately $297.2 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both added new positions, each holding over 2.9 million shares.
Rhythm Pharmaceuticals, Inc. Stock Down 17.5%
Shares of RYTM were trading at $88.38. The stock has been seeing positive analyst sentiment, with several firms maintaining a buy rating.
$RYTM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.
On May 18, 2026, Smith Hunter, the Chief Financial Officer, sold 3,000 shares and bought another 3,000 shares at an average price of $17.87. On May 15, 2026, Christopher Paul German, the Corporate Controller & CAO, executed multiple transactions including buying 4,442 shares and selling 4,643 shares at an average price of $92.21. Yann Mazabraud, EVP and Head of International, sold 12,875 shares on April 1, 2026.
Analysts Set New Price Targets
On June 15, 2026, Wells Fargo maintained its buy rating on RYTM, setting a price target of $155. Canaccord Genuity also maintained a buy rating with a $143 target on May 7, 2026. RBC Capital followed suit with a $137 target on May 6, 2026. The consensus among analysts is a buy rating, with a mean target price reflecting continued confidence in the stock.
Bottom Line
Wells Fargo's reaffirmation of a buy rating for RYTM with a $155 target underscores the positive sentiment surrounding the stock. Investors keep a close eye on such ratings as they provide insights into the stock's potential performance. It's important to note that analyst ratings are based on various factors and should be considered as part of a broader investment strategy.
Get Rhythm Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RYTM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.